tbuckley/cabot-search huggingface dataset:
Management of pathologic fractures through unicameral bone cysts
Authors: P. R. Robins
Journal: JAMA (1972)

Pathologic fracture through all but small and resolving unicameral cysts should be treated by surgery because healing seldom occurs spontaneously. The following are recommended: (1) immobilization of fracture until stability in acceptable alignment is achieved; (2) when the epiphysis has grown a safe distance away from the cyst and after confirmatory open biopsy, a subperiosteal full cortical thickness excision is performed, encompassing up to three fourths of tubular circumference, and the medullary surface of the remaining cortical bone is excoriated; and (3) defect is packed with autogenous bone.
Knowing Ron
Authors: Phyllis L. Spechko
Journal: JAMA (1985)

I met Ron in April 1984 at the outpatient clinic for gay men at the medical center where I work with patients with AIDS; he had had AIDS for a year. He eyed me critically that first evening for evidence of competence, while I noted the signs of his chronic, progressive illness. His skin was pale and slightly gray. He was thin and angular, his clothes now two sizes too large for him. He walked with a noticeable unsteadiness and appeared exhausted at 5:30 in the evening. I immediately identified with him. Both of us were educated in private high schools and small, Western colleges, and we were the same age. We were both from conservative, upper-middle-class families. Ron was independent, hard working, well groomed, articulate, and opinionated, but it was his subtle, convoluted, sometimes self-effacing sense of humor that most appealed to me. I saw Ron every two weeks
&lt;TITLE&gt;Maintaining good health&lt;/TITLE&gt;
Journal: JAMA (1999)

and the AMA.The information and recommendations appearing on this page are appropriate in most instances; but they are not a substitute for medical diagnosis.For specific information concerning your personal medical condition, JAMA and the AMA suggest that you consult your physician.This page may be reproduced noncommercially by physicians and other health care professionals to share with patients.Any other reproduction is subject to AMA approval.
Development and early natural history of HTLV-III antibodies in persons with hemophilia
Authors: M. E. Eyster
Journal: JAMA (1985)

Antibodies to human T-cell lymphotropic virus type III (HTLV-III) were first detected in 1979 in serum samples from 30 known seropositive patients with hemophilia, over half of whom seroconverted in 1981-1982. Lymphadenopathy was present in 70% who were seropositive more than three years, compared with 10% who were seropositive three years or less. T-helper cell counts were low (307 ± 64 cells/cu mm) in the early seroconverters, and normal in the late seroconverters. T-suppressor cell counts were not related to the year of seroconversion. The long latency period after seroconversion suggests an ongoing indolent process, rather than an acute infection. It remains to be determined whether this is an aberrant part of the immune response initiated by HTLV-III antigens or the result of a chronic active HTLV-III infection. (<i>JAMA</i>1985;253:2219-2223)
MEDICINE AS AN EXACT SCIENCE.
Authors: W. J. K. KLINE
Journal: JAMA (1997)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Combination of AFP, AFP-l3 and PIVKA-II levels improves diagnostic accuracy of hepatocellular carcinoma (ALPS score)
Authors: Han Ah Lee, Tae Hyung Kim, Young-Sun Lee, Young Kul Jung, Ji Hoon Kim, Hyung Joon Yim, Jong Eun Yeon, Kwan Soo Byun, Soon Ho Um, Yeon Seok Seo
Journal: Journal of Hepatology (2020)
Correction
Authors: Justin Pepperell, Chris Davies, Mark Elliot, Renata Riha, Andrew Cummin, Lee Dowson, John White, Anita Simmonds, John Gibson, Barbara Winter, Rebecca Mason, Massimilliano Siccoli, Jacqui Webb, Suber Valmiki, Elizabeth Thorne, Nurit Fox, Margaret Chapman, Marjorie Vennelle, Craig Armstrong, Loiuse Spragg, Ramesh Ghiassi, Gillian Twigg, Neil Ward, Jayne Pateraki Trial Management, Emma Hedley, Nicky Crosthwaite, Claire Manners, Magda Laskawiec Data Management, Thomas Penning, Anna Bara, Peter Stradling, Phillipa Davies, Jenny Stradling, Adam Smith, Alice Roberts We
Journal: Thorax (2012)
Growth of the Soil.
Journal: JAMA (1921)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
OS4.1 MEVITEM: A European, randomized, open-label, Phase I/II study of vismodegib in combination with temozolomide versus temozolomide alone in adult patients with recurrent or refractory medulloblastoma presenting an activation of the Sonic Hedgehog (SHH) pathway
Authors: D Frappaz, M Barritault, L Montané, F Laigle-Donadey, O Chinot, E Le Rhun, A Bonneville-Levard, D Meyronnet, G Garin, D Pérol
Journal: Neuro-Oncology (2019)

Abstract BACKGROUND Vismodegib (V) suppresses sonic hedgehog (SHH) signaling. We postulated that vismodegib together with chemotherapy may be more efficient than chemotherapy alone in patients (pts) relapsing of a SHH-activated medulloblastoma (MB). MATERIAL AND METHODS Adult pts with recurrent SHH-MB not previously exposed to temozolomide (T) were randomly assigned (2:1 ratio) to Arm A (V daily 150mg/d, po) + T (D1-5: 150 mg/m2 for cycle 1 and 200 mg/m2 thereafter; n=up to 25pts) or Am B (T alone; n=up to 13pts). Identification of SHH activation was performed centrally by IHC (GAB1, β-catenin, filamin A, and YAP1). NGS analyses were performed to identify the mutations responsible for SHH activation. Primary objectives were to assess the incidence of severe toxicities (safety run-in based on a 3 + 3 design) and the 6-month non-progression rate (NPR-6m) according to WHO criteria and based on central read tumor assessment (Phase II). A Minimax Simon’s two-stage design was used to detect NPR-6m of 55% (p0: 30%, type I error rate of 5%, power of 80%). At first stage, ≥ 3/9 pts without progression at 6m were required for the accrual of 16 additional pts in Arm A. A 3rd independent and parallel arm with V as single agent (Arm C, n= up to15pts) was added for pts previously treated by T. RESULTS 24 SHH-MB pts were enrolled (Arm A: 10, Arm B: 5 and Arm C: 9; median age: 37 y [21–55]). At the end of the safety run-in; no major safety concerns were reported. At the end of Stage I: no objective response were reported and 2 pts among 10 were free of progression at 6m among in Arm A. According to statistical rules, the study was definitively closed to enrolment. NGS analyses showed a PTCH1 inactivating mutation in 6 pts (n=4 in arm A; n= 2 in arm B); a SMO activating mutation in 4 pts (n= 3 in Arm A; n=1 in Arm B). For 1 pt in each arm, no tumor sample was available for analysis, for 1 pt in Arm A DNA quality was insufficient, and for 1 patient in each arm no mutations of SMO, PTCH1, SUFU or SHH were found. Out of the 4 pts in Arm A with an inactivating PTCH1 mutation, only 1 was progression free at 6m. PFS and OS data will be presented at the meeting. CONCLUSION The combination of vismodegib with monthly T failed to demonstrate superior activity as compared with T alone. Further studies are warranted to refine therapeutic indication for vismodegib
Modern Treatment in General Practice
Journal: JAMA (1934)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 2665: Zinc dysregulation as an emerging molecular target in epithelial cancers
Authors: Jessica Perer, Rebecca Justiniano, Anh Hua, Georg T. Wondrak
Journal: Cancer Research (2019)

Abstract Zinc plays an established role in structure and function of enzymes and transcription factors, and zinc signaling has now been recognized as a molecular determinant of epithelial differentiation and cell fate. Intracellular zinc homeostasis is regulated by zinc importers (ZIPs encoded by the SLC39A gene family). Cumulative evidence suggests that dysruption of zinc homeostasis is an emerging hallmark of various tumor types, characterized by downregulation of ZIP expression upstream of intracellular zinc depletion. In nonmelanoma skin cancer (NMSC) examined in TMA format we have observed downregulation of ZIP2 (involved in epidermal differentiation) that occurs with zinc depletion and impaired differentiation. Likewise, in pancreatic ductal adenocarcinoma (PDAC) tumor tissue, downregulation of ZIP3 and zinc depletion are detectable. We therefore tested feasibility of pharmacological induction of intracellular zinc overload for chemotherapeutic intervention. Using the small molecule ionophore ZnPT (zinc pyrithione) as an experimental chemotherapeutic, rapid induction of zinc overload followed by metal stress response signaling and cell death were observable in a panel of malignant epithelial cell lines (NMSC: SCC-25; HaCaT-ras II-4; PDAC: BxPC-3, MIA PaCa-2, PANC-1). Remarkably, PDAC cell lines displayed nanomolar sensitivity to ZnPT-induced cytotoxicity. In BxPC-3 cells, pronounced upregulation of stress response gene expression (MT2A, HSPA6, HMOX1) and signaling (p-p38, p-eIF2α, HO-1) was detectable within one hour of ZnPT exposure. Accumulation of protein-ubiquitin conjugates further substantiated the rapid occurrence of ZnPT-induced proteotoxic stress and UPR, consistent with a role of ZnPT in the inhibition of proteasome-associated deubiquitinating enzymes (DUBs). Next, we confirmed NMSC-directed anti-tumor activity of ZnPT in a photocarcinogenesis SKH1 mouse model, followed by exploratory chemotherapeutic intervention targeting BxPC-3 PDAC xenografts. Taken together, our data suggest that ZIP-based dysruption of intracellular zinc homeostasis may be a valid molecular target in specific epithelial cancers. [This research was funded in part by NCI: P30 CA023074 &amp; R03 CA230949.] Citation Format: Jessica Perer, Rebecca Justiniano, Anh Hua, Georg T. Wondrak. Zinc dysregulation as an emerging molecular target in epithelial cancers [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 2665.
Table of contents
Journal: Hepatology (2020)

Cover Figure: Davidson and colleagues review the major pathways and dominant genetic modifiers known to be relevant players in human NAFLD and which may determine key components of the heritability of disease traits including steatosis and fibrosis.In this figure, the major pathways involved in lipid trafficking, compartmentalization, and use are represented within boxes, each of which undergoes regulation through a combination of host genetic factors and environmental interactions.See review on page 330.
Early Southern Italian Medicine
Journal: JAMA (1989)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Adjuvant radiotherapy and regional lymph node field control in melanoma patients after lymphadenectomy: Results of an intergroup randomized trial (ANZMTG 01.02/TROG 02.01)
Authors: M. A. Henderson, B. Burmeister, J. F. Thompson, J. Di Iulio, R. Fisher, A. Hong, R. Scolyer, K. Shannon, H. Hoesktra, J. Ainslie
Journal: Journal of Clinical Oncology (2009)

LBA9084 Background: Adjuvant radiotherapy (RT) is an option for patients with isolated regional recurrence of melanoma considered to be at high risk of further regional recurrence after lymphadenectomy. This is the first completed study to assess the effects of RT on regional recurrence, survival, morbidity and quality of life (QOL) in these patients. Methods: Multicenter randomized study of patients with isolated regional recurrence at increased risk (>25%) of regional recurrence. Eligibile patients included ≥1 parotid, ≥ 2 cervical or axillary or ≥ 3 groin nodes or extra nodal spread of tumor or maximum metastatic node diameter ≥3cm in neck or axilla or ≥4cm in the groin. Patients were randomized to observation or regional nodal basin RT (48Gy in 20 fractions) after lymphadenectomy. Regional recurrence was the primary end point and morbidity, QOL, patterns of relapse, disease free and overall survival were secondary end points. The target sample size was 220 patients, which would enable a difference in 3 year regional relapse (cumulative incidence) rates of 30% versus 15% to be detected with a power of 80% (using a two sided logrank test at the 5% level of significance). Results: 250 pts were randomized from 16 centers from March 2002 to September 2007. There were 123 in the RT group and 127 in OBS group. 2 pts withdrew consent and 31 were excluded from analysis of the main objective following an independent blinded review of eligibility compliance by two reviewers. 227 pts were available for analysis of the main objective (109 RT, 108 OBS). Median follow-up was 27 mo. There was a statistically significant improvement in lymph node field control with radiotherapy, 20 RT pts and 34 OBS pts relapsed (HR 1.77 1.02–3.08 p=0.041). Median survival times were 2.6 years (RT) and 3.9 years (OBS) p=0.14. Conclusions: Adjuvant RT improved regional control in melanoma patients at high risk of regional relapse after lymphadenectomy. An effect on survival was not demonstrated. No significant financial relationships to disclose.
Correction: Heart valve records falsified
Journal: BMJ (1992)

care, the number of patients who are assigned to aggressive ambition and hence loses many with the government have offered the following, which generalists is far lower than the number Marsh more caring qualities, an emphasis that the women is what every junior doctor wants?proposes.Thus Marsh's statement that what in our care would doubtless reverse.In addressing(1) Non-medical staff trained to carry out should be done can be done in half the number of these problems the college must clarify its attitude phlebotomy, intravenous drug administration, visits is not supported by the American experience, to research and ensure that training can be electrocardiography, portering, and routine We have half the number of visits, twice the cost completed within the NHS.clerical work and to find empty beds.for the same level of care, and far less effective DAVID HOWE(2) Overtime pay equal to daytime rates.prevention than in the United Kingdom.Department of Obstetrics and Gynaecology, (3) A half day off work after a busy night on call.General practice in Britain is, with all of its Princess Anne Hospital, The government's failure to implement these faults, a model of efficient, personalised, accessible Suthampton S09 4HA demands boldly and swiftly indicates a brutality care compared with what is available in other IButSTringnobercs M71930146(7
Prostate Cancer
Authors: John L. Zeller
Journal: JAMA (2008)

Prostate CancerT he prostate is a walnut-sized gland located just below the bladder in men.It surrounds the top portion of the male urethra (the tube that transports urine and semen out of the body).The gland' s main function is to produce semen (a thick fluid that nourishes and transports sperm).Prostate cancer (an abnormal, uncontrolled growth of cells originating in the prostate gland) is the most common cancer, and the second leading cause of cancer deaths, among American men.Although the majority of men who reach age 80 are found to have prostate cancer, this condition alone may not contribute to serious harm if it does not spread.The July 9, 2008, issue of JAMA includes an article about treatment of prostate cancer.This Patient Page is based on one previously published in the November 15, 2006, theme issue of JAMA.
Deaths
Journal: JAMA (1966)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
TOC 5th page
Authors: Robert Annett, Janet Brody, David Scherer, Elizabeth Perkett, Scott Sicherer, Suzanne Teuber, Neomi Wolff, Shmuel Yannai, Nathan Karin, Yael Levy, Ram Reifen, Ilan Dalal, Uri Cogan, Benjamin Cohen, Sally Noone, Anne Mun ˜oz-Furlong, New York, Fairfax Va, Tamara Perry, Elizabeth Matsui, Mary Conover-Walker, Robert Wood, Merima Bublin, Adriano Mari, Christof Ebner, Andre ´knulst, Otto Scheiner, Karin Hoffmann-Sommergruber, Heimo Breiteneder, Christian Radauer, Maria Giustizieri, Cristina Albanesi, Joachim Fluhr, Paolo Gisondi, Johannes Norgauer, Giampiero Girolomoni, Roland Kaufmann, Regina Fo ¨lster-Holst, Peter Ho ¨ger, Helena Lo ¨ffler, Doris Staab, Matthias Bra ¨utigam
Journal: Journal of Allergy and Clinical Immunology (2004)
QOL-52. USE OF CANNABINOIDS IN THE PEDIATRIC CENTRAL NERVOUS SYSTEM TUMOR POPULATION
Authors: Kathleen Dorris, Jessica Channell, Molly Hemenway, Angelina Baroffio, Michael Ellison, Natalie Brionse, Andrea Griesinger, Andrew Donson, Jennifer Madden, Colleen Van Essen, Jean Mulcahy Levy, Daniel Ambruso, Nicholas Foreman
Journal: Neuro-Oncology (2018)

Cannabinoids, including cannabidiol (CBD) and tetrahydrocannabinol (THC), are a class of compounds found in marijuana. Numerous studies in adults have examined cannabinoid use in management of cancer-related symptoms such as nausea, anorexia, and pain. Less is known about the use in the pediatric oncology population. Lay interest is also increasing in cannabinoid use as anticancer therapy for pediatric central nervous system (CNS) tumors. A prospective observational study is underway at Children's Hospital Colorado to evaluate cannabinoids' impact on quality of life using PedsQL™ 4.0 modules of pediatric CNS tumor patients who self-medicate with cannabinoid products. Laboratory assessments of neutrophil function, T-cell activity and pharmacokinetics of CBD, THC and associated metabolites are in process. Diaries collect exploratory information on cannabinoid use patterns. To date, 26 patients (13:13; male:female) have been enrolled with a median age of 6.6 years (range, 3.3-17.3 years). The most common tumor type in enrolled patients was embryonal tumors (10/26); 8/26 patients had low-grade glioma/glioneuronal tumors and 6/26 had high-grade gliomas. Eleven patients initiated cannabinoids concurrent with upfront standard treatment regimens. Five patients completed 12 months of cannabinoid therapy on study; 12 patients are off study after <12 months of therapy. Nine patients continue on cannabinoid therapy and remain in follow up. New enrollment continues. Preliminary immune function analyses identified impaired neutrophil superoxide anion production but normal directed migration in patients taking cannabinoids. Families of children with various CNS tumors are pursuing cannabinoid therapy for both antitumor purposes and supportive care.